Ignite Creation Date:
2024-05-06 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05257395
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-02-25
First Post:
2022-02-16
Brief Title:
A Study of XZP-3287 in Combination With LetrozoleAnastrozole in Patients With Advanced Breast Cancer
Sponsor:
Xuanzhu Biopharmaceutical Co Ltd
Organization:
Xuanzhu Biopharmaceutical Co Ltd
Study Overview
Official Title:
A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 Combined With LetrozoleAnastrozole Versus Placebo Combined With LetrozoleAnastrozole in Patients With HR Positive and HER2 Negative RecurrentMetastatic Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III clinical trial designed to evaluate the efficacy and safety of XZP-3287 in combination with LetrozoleAnastrozole versus placebo in combination with LetrozoleAnastrozole in patients with HR-positive and HER2-negative recurrentmetastatic breast cancer who have not received systemic anticancer therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None